COMMUNIQUÉS West-GlobeNewswire

Real-Time Intoxication Detection Platforms Target Expanding Multibillion-Dollar Healthcare Opportunities
13/05/2026
AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from traffic enforcement and [...]
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
13/05/2026
AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world today, contributing [...]
SS Innovations Reports First Quarter 2026 Financial Results
13/05/2026
Record quarterly revenue driven by strong growth in SSi Mantra installations and procedures FORT LAUDERDALE, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations [...]
Amlogenyx Presents Preclinical Data on AM805, a Potentially Transformative Investigational Gene Therapy for Alzheimer’s Disease
13/05/2026
A novel approach using a lysosomal enzyme to prevent and reverse amyloid accumulation inside as well as outside neurons, with greater potency, delivered in a one-time gene therapy The therapeutic strategy has the [...]
Rectify Pharmaceuticals to Present Preclinical Data on New Dual Targeted ABCB4/BSEP Positive Functional Modulator at EASL 2026
13/05/2026
Data highlight RTY-406's dual ABCB4/BSEP mechanism and marks the first demonstration of proof of mechanism in a non-human primate model that closely mirrors the human hepatobiliary system BOSTON, May 13, 2026 (GLOBE [...]
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
13/05/2026
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
13/05/2026
MINNEAPOLIS and BRISBANE, Australia, May 13, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, [...]
Cannabix Marijuana Breath Test Achieves Major Milestone: Breath Collection Unit Secures UL and CSA Certifications
13/05/2026
VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to announce that its portable Breath Collection [...]
Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors
13/05/2026
BASEL, Switzerland, May 13, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, [...]
HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026
13/05/2026
Tuebingen , Germany, May 13 , 202 6 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, announces that its abstract highlighting clinical [...]
IBA introduces AdaPTinsight XR, the next generation of CBCT imaging for image-guided proton therapy
13/05/2026
Proton therapy CBCT imaging solution across Proteus ® Portfolio providing clarity and confidence in IGPT Louvain-la-Neuve, Belgium, May 13, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle [...]
Inventiva to Present Abstracts at the EASL Congress 2026
13/05/2026
Daix (France), New York City (New York, United States) , May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development [...]
Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026
13/05/2026
Daix (France), New York City (New York, Etats-Unis), le 13 mai 2026 – Inventiva (Euronext Paris et NASDAQ: IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique au stade clinique spécialisée dans le [...]
Fortis Life Sciences attribue la subvention à la découverte AbNano® VHH Discovery 2026 à Deliver Biosciences pour la recherche sur l’administration ciblée de médicaments
13/05/2026
Le programme de subvention élargit l’accès aux technologies d’anticorps à domaine unique avancées, afin de soutenir la recherche et le développement des traitements de nouvelle génération BOSTON et LONDRES, 13 mai 2026 [...]
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
13/05/2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]
Fangzhou Showcases “AI+H2H” Chronic Disease Service Innovations at the National Intelligent Medicine Conference
13/05/2026
WUHAN, China, May 13, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, participated in the 2026 National Medical Industry [...]
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
13/05/2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced [...]
Valneva publie ses résultats financiers audités et consolidés pour le premier trimestre 2026
13/05/2026
Ventes de produits de 30,5 millions d’euros Position de trésorerie de 105,3 millions d’euros à fin mars 2026, hors produit de la levée de fonds réservée réalisée avec succès en avril 2026 1 Lancement, en avril 2026, d’ [...]
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates
13/05/2026
Total product sales of €30.5 million Cash position of €105.3 million as of end March 2026, excluding proceeds from successful reserved offering completed in April 2026 1 Program launched in April to further reduce [...]

Pages